High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer. oncological outcomes after a median 15-year follow-up - Behmueller, Manuel (Verfasser); Tselis, Nikolaos (Verfasser); Zamboglou, Nikolaos (Verfasser); Zoga, Eleni (Verfasser); Baltas, Dimos (Verfasser); Rödel, Claus (Verfasser); Chatzikonstantinou, Georgios (Verfasser) (Universität, 2022)